Ibrance vs Jakafi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Ibrance costs 5% less per claim than Jakafi ($10816.00 vs $11432.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Jakafi at $2.7B.
| Metric | Ibrance | Jakafi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $10,816* | $11,432 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.5B | $2.7B |
| Total Claims | 418,000 | 236,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -5.6%* | 11.2% |
| Generic Available | Yes | No |
| Condition | Cancer | Cancer |
| Total Beneficiaries | 36,000 | 22,000 |
Ibrance costs 5% less per claim than Jakafi ($10816.00 vs $11432.00). Ibrance has a generic alternative available. Total Medicare spending: Ibrance at $4.5B vs Jakafi at $2.7B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Ibrance and Jakafi. What follows is the interpretation — which specific axes carry the most weight for Ibrance versus Jakafi, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.